Biohaven Pharmaceutical Holding Company Ltd.
BHVN
BHVN was delisted on the 3rd of October, 2022.
223 hedge funds and large institutions have $5.7B invested in Biohaven Pharmaceutical Holding Company Ltd. in 2021 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 93 increasing their positions, 67 reducing their positions, and 39 closing their positions.
40% more funds holding in top 10
Funds holding in top 10: 10 → 14 (+4)
39% more capital invested
Capital invested by funds: $4.1B → $5.7B (+$1.6B)
39% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 67
16% more call options, than puts
Call options by funds: $92.9M | Put options by funds: $79.8M
0% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 39
0% less funds holding
Funds holding: 224 → 223 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$107M |
| 2 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$74.7M |
| 3 |
BlackRock
New York
|
+$73.7M |
| 4 |
AG
Artal Group
Luxembourg
|
+$32.5M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$125M |
| 2 |
RM
RP Management
New York
|
-$81.2M |
| 3 |
AC
Armistice Capital
New York
|
-$40.6M |
| 4 |
KCM
Kingdon Capital Management
New York
|
-$37.3M |
| 5 |
EP
Eversept Partners
New York
|
-$16.6M |
BHVN Hedge Fund Activity: Q2 2021 in Review
223 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q2 2021, worth a combined $5.7B — up 39% from $4.1B a quarter earlier.
Fund positioning in BHVN was balanced in Q2 2021: 39 funds opened new positions, 39 closed out, 93 added to existing stakes and 67 trimmed.
The largest buyer was Capital World Investors, adding an estimated $107M. The largest seller was Wellington Management Group, cutting an estimated $125M.
- 223 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q2 2021, down from 224 in Q1 2021.
- Funds reported $5.7B of Biohaven Pharmaceutical Holding Company Ltd. stock for Q2 2021, up 39% quarter-over-quarter.
- 39 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q2 2021 and 39 closed out, a net change of 0 holders.
- The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q2 2021 was Capital World Investors, an estimated $107M added.
- The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q2 2021 was Wellington Management Group, an estimated $125M sold.
Based on aggregated 13F filings for Q2 2021.